Primary facial nerve paraganglioma: report and review of the literature
- 1 Department of Otolaryngology/HNS, Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, USA
- 2 Department of Pathology, Louisiana State University, Shreveport, Louisiana, USA
- Correspondence to Dr Gauri Mankekar; gmanke@lsuhsc.edu
Abstract
This report describes the diagnosis and treatment of a patient with a rare primary facial nerve paraganglioma as well as a review of the current literature. A 60-year-old male patient presented to our clinic with a 4-month history of left-sided progressive facial paralysis House-Brackmann V. Biopsy taken during facial nerve (FN) decompression confirmed the diagnosis of paraganglioma. The left FN was sacrificed during resection of the mass and a 12-7 jump graft, using the left greater auricular nerve, was performed with acceptable outcomes. The rarity of these tumours does not discount their clinical importance or the necessity to include them in the differential when presented with unilateral FN paralysis. Investigation should begin with CT and MRI imaging to identify and localise the potential mass. Histologic confirmation requires tissue. While surveillance imaging is occasionally an option, often complete surgical resection of the mass and sacrifice of the nerve is necessary.
Background
Paragangliomas (PGLs) are an important differential to include when dealing with head and neck soft tissue tumours. Whether arising from the facial nerve (FN) itself or nearby structures, they commonly present as progressive FN paralysis and can easily be mistaken for other, non-neoplastic conditions. Treatment of these tumours almost always consists of complete surgical excision. Delays in proper diagnosis and treatment may lead to permanent FN paralysis, emphasising the importance of this rare disease.
Case presentation
A 60-year-old Caucasian man presented with a 4-month history of progressive left-sided facial paresis that began as mild facial twitching. Steroid treatment at the time for presumptive Bell’s palsy produced no improvement and his symptoms continued to worsen. Examination revealed House-Brackmann (HB) VI/VI left facial palsy. He could no longer close his left eyelid and had to tape it shut at night. He had recently noticed increased dryness of his eyes in the morning. No vision changes, voice irregularity or loss of sensation were noted. Otoscopic examination was within normal limits. He was a non-smoker and did not drink alcohol. No relevant prior medical history was noted.
Investigations
Prior to referral to otolaryngology, the patient’s primary care physician had already begun investigation into his condition. In March, 4 months prior to his referral visit, the patient began experiencing mild left facial twitching and paralysis. Suspecting potential viral aetiology, treatment was initially attempted with oral glucocorticoids. By June, his condition progressed and he could no longer completely close his left eyelid. MRI of the head with and without contrast was performed. This revealed a small lobulated, enhancing mass lesion along the inferior portion of the descending mastoid segment of the left FN and left stylomastoid foramen.
At referral visit, these findings were found to be suspicious for an FN schwannoma. Audiogram performed at this time revealed essentially normal hearing from 250 Hz to 8000 Hz on the patient’s right ear. However, on the left ear, the patient was found to have a sloping mild-to-moderate sensory neural hearing loss at 2000–8000 Hz. Hearing between 250 Hz and 2000 Hz was normal. Speech reception threshold and Word Recognition Scores were within normal limits bilaterally. Dedicated MRI of the head with and without intravenous contrast revealed a lobulated, expansile lesion involving the distal mastoid segment of the left FN and left stylomastoid foramen with mild extension to the surrounding mastoid air cells (figure 1). With the differential diagnosis, then being FN schwannoma versus haemangioma, CT scan of the temporal bone with and without contrast was performed. This revealed a 19 mm×9 mm×9 mm soft tissue mass in the mastoid segment of the left FN as well as a focus of ‘honeycomb bone’ at the mass’ posterior aspect (figure 2). With this new evidence, the differential shifted to include either a haemangioma or possibly a skip lesion from some other malignant process. Nerve conduction studies and Electromyography (EMG) testing were instead performed on both FNs. The conduction study, performed via bilateral nasalis muscles, revealed compound muscle action potentials (CMAPs) of normal amplitude and frequency on the right. No CMAPs could be obtained from the left FN. Needle electrode examination revealed denervation of both the left frontal and orbicularis oculi muscles. No voluntary activity was identified. These findings were consistent with severe damage to the left FN and provided the need for urgent intervention to salvage nerve function.
Axial MRI showing a lobulated mass in the left distal mastoid segment.
Axial (A) and coronal (B) CT scans show ‘honeycomb’ bone in the distal mastoid bone at the stylomastoid foramen.
Treatment
Following the nerve study results, a surgical team lead by an experienced neuro-otological surgeon performed a mastoidectomy with transmastoid FN decompression and nerve biopsy. During the procedure, the tympanic portion of the FN was found to be severely edematous and abnormally enlarged. Tracing the nerve inferiorly, a 2 cm mass was identified arising from the FN near the mastoid tip. Surrounded in a fibrous capsule, the mass’ location and size were consistent with previous CT scan/MRI findings. During excision, the mass was revealed to be arising from nerve itself. This was revealed when the epineurium was identified surrounding the mass as opposed to being simply adjacent to it. The later organisation being what would be expected with other such neoplasms such as haemangioma.
Biopsies were initially taken from the epineurium and sent for frozen. Results returned as non-diagnostic. The facial nerve was therefore traced back to the stylomastoid foramen and further samples were taken, for total of 25, and sent for permanent. A diagnosis of primary FN PGL was confirmed by histology. The classic nesting pattern of chief cells with abundant granular cytoplasm and evenly dispersed nuclear chromatin was consistent with neuroendocrine differentiation. The tumour displayed a prominent fibrovascular stroma between the nests (figure 3). Neuroendocrine origin was confirmed by diffuse positivity with synaptophysin (figure 4). The accompanying sustentacular cells at the periphery of the nests were highlighted with S100 (figure 5).
Nested arrangement of neuroendocrine cells surrounded by fibrovascular stroma (H&E ×20).
Synaptophysin-positive tumour cells confirming neuroendocrine differentiation (synaptophysin ×20).
S100-positive sustentacular cells at the periphery of tumour cell nests (S100, ×20).
Following recovery, treatment options were discussed with the patient and his family. These included observation, radiation and/or complete surgical excision of the mass and involved nerve with subsequent nerve grafting. The risks and benefits of each option were thoroughly explained for each option as well as for the option of not receiving treatment at all. Emphasis was made that excision and grafting would require at least 1 year of postoperative care and could potentially return his nerve function to an HB III/VI, at best. The patient was elected for excision and grafting.
With the goal to aid in surgical tumour removal, 3 days prior to surgery, an interventional radiology team successfully immobilised the tumour feeder vessel at the occipital branch of the left external carotid artery using embolic TRUFILL n-butyl cyanoacrylate.
The mass was completely excised subsequently and required superficial parotidectomy and with sacrifice of the FN. The left greater auricular nerve was then used for FN anastomoses via 12-7 jump graft to the left hypoglossal nerve. Final pathology of the mass revealed type I (chief) cells, which stained positive for chromogranin A and synaptophysin. An S-100 stain was also positive in scattered type 2 (sustentacular) cells.
Outcome and follow-up
One year postoperatively, the patient’s left face remained HB VI/VI and he exhibited significant left lagophthalmos that required he tape his left eye shut at night. He remained HB VI/VI on the left 2 years after his initial surgery and it was at this point that the patient elected to undergo facial reanimation surgery. Postoperatively, the patient reported drastic improvement in his symptoms. Overall the left facial nerve function was improved with his left forehead, eye and mouth, now HB IV/VI, HB II/VI and HB V/VI, respectively. The patient’s sloping mild-to-moderate sensorineural hearing loss in the 2000–8000 Hz frequencies on the left remained unchanged from the preoperative assessment.
Discussion
Pheochromocytomas of the adrenal gland currently make up 90% of paraganglionic cell tumours. The remaining 10% occur at extra-adrenal sites and are labelled PGLs. Of these, 3% occur in the head and neck region. Of all head and neck tumours, PGLs make up 0.6% and occur at a rate of ~1/30 000 in the general population.1 2 With the rarity of head and neck PGLs in mind, it is no mystery why only 21 cases of primary FN PGLs, two of which lack histological confirmation, were found in the literature. The patient in this report represents the 22nd such case and the 20th with histological confirmation.3
Unilateral progressive facial paralysis is the most common initial symptom in patients with PGL followed by pulsatile tinnitus.4 In a report by Yuhan et al, 73.1% and 42.1% of patients reported these symptoms, respectively. While paralysis occasionally presented acutely, the mean time of progression was 17.8 months.3 Other potential symptoms include aural fullness, disequilibrium, vertigo, hearing loss and otalgia.4 5 Of note, in patients with jugulotympanic PGLs, pulsatile tinnitus may be the initial symptom.6
Formation of a differential diagnosis should begin with investigative imaging and include schwannoma, vascular neoplasms such as haemangioma, local extension from jugular PGL, cholesteatoma and metastases from carcinoma.3 On CT scan, circumferential widening of the facial canal is a classic finding. Ninety four per cent of tumours occur at either the distal canal or stylomastoid foramen.4 A ‘moth-eaten’ pattern of bony destruction may also be seen in 50% of patients. This finding aids in narrowing the diagnosis as it is not found in neuromas.6 An example of this pattern is seen in this patient via the focus of ‘honeycomb bone’ posterior to the tumour. On MRI, PGLs appear isointense to muscle on both T1-weighted and T2-weighted imaging. Hypervascular in nature, all PGLs highlight with gadolinium contrast. T1-weighted imaging may reveal areas of hypointensity appearing as a classic ‘salt and pepper’ pattern. This is usually only seen in tumours>2 cm and is believed to represent areas of increased vascular flow. Lastly, increased uptake on MRI may help distinguish PGLs from cholesteatomas on differential.
Digital subtraction angiography aids in diagnosis of PGL while allowing for mapping of tumour vasculature and preoperative embolisation. In smaller tumours (<1 cm) however, F-dihydroxyphenylalanine positron-emission tomography is becoming increasingly used for diagnosis over MRI and has potential for future use as a screening tool in those with hereditary PGL disorders.2 7 When deciding whether or not to treat patients with PGL, it is important to individualise to the patient. Asymptomatic patients without significant compromise in FN function may be treated conservatively. This may consist of regular surveillance imaging as well as FN decompression.3 Patients with symptomatic involvement of the FN, however, require surgery for resection of the tumour while attempting to preserve any residual nerve function. Prior to excision however, a biopsy of the tumour should be taken for histological analysis. Targeted immunohistochemistry is used to aid diagnosis via staining for PGL-specific endocrine markers. Spindle and/or polygonal-shaped type I cells (chief cells) can be seen arranged in nests (Zellballen pattern) and surrounded by sustentacular, type II cells.8 Type I cells will typically stain positive for chromogranin A and synaptophysin while type II cells will stain positive for S-100 (figure 6).9
Synaptophysin-positive neuroendocrine cells with surrounding S100-positive sustentacular cells (inset) (synaptophysin and S100, ×20).
If function is compromised due to local tumour compression, microdissection of the tumour away from the nerve may be attempted. However, if infiltration has occurred, sacrifice of the FN is required along with complete resection of the tumour.9 This risks further nerve damage and should be reserved for those with an HB score of IV/VI or worse.10 In such cases, reinnervation via nerve grafting is often performed. The greater auricular nerve is most often used with the sural nerve being a common second option.4 It is important for physicians to be aware that facial function recovery will not exceed HB III/VI, even with successful grafting.3
Patient’s perspective
Originally, when the facial paralysis began, the doctors diagnosed me with Bell’s palsy. It turned out that was not the case. After several appointments, I received my diagnosis. The facial paralysis left me distraught, but after having a gold weight put in my left eyelid, therapy and plastic surgery at LSU Shreveport, I felt and still feel much better about the entire situation. I am grateful for everything the team of doctors has done for me.
Learning points
-
Paragangliomas (PGLs) are benign and highly vascular neural crest cell tumours.
-
Primary PGLs of the facial nerve (FN) are extremely rare.
-
While it is possible to present acutely, the most common symptom in primary FN PGL is unilateral, progressive facial paralysis and early identification is paramount to preserve FN function.
-
CT scan and MRI aid in diagnosis but confirmation requires tissue biopsy.
-
Surgical resection of the entire tumour with sacrifice of the FN is the primary treatment modality.
Footnotes
-
Contributors JAB collected the patient data and research data for the manuscript. He wrote, edited and submitted the manuscript for review. He also contacted and gained consent from the patient to submit the manuscript and the information contained within. CAON assisted in the proofreading and editing of the manuscript and provided an expert opinion on the data. She also provided general administrative assistance during the writing of this manuscript. ABF assisted in obtaining and describing the histological images of the patients’ pathology. She also provided her expert opinion on various diagnostic techniques used in this manuscript. GM assisted in collecting patients data from the electronic health record, assisted in proofreading and editing the manuscript, and, as a board certified neurotologist, provided expert knowledge of the topic of paraganglioma.
-
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
-
Competing interests None declared.
-
Patient consent for publication Obtained.
-
Provenance and peer review Not commissioned; externally peer reviewed.
- © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.
References
Use of this content is subject to our disclaimer